Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Methods Mol Biol. 2012;821:349-59. doi: 10.1007/978-1-61779-430-8_22.

Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

Author information

  • 1Department of Neurology, University of California, San Francisco, CA, USA. qiwen.fan@ucsf.edu

Abstract

Amplification of the gene encoding the epidermal growth factor receptor (EGFR) occurs commonly in glioblastoma (GBM), leading to activation of downstream kinases, including phosphatidylinositol 3'-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR). A serine-threonine kinase, mTOR controls cell growth by regulating mRNA translation, metabolism, and autophagy; acting as both a downstream effector and upstream regulator of PI3K. These signaling functions are distributed between at least two distinct complexes, mTORC1 and mTORC2 with respect to pathway specificity. We have investigated mTOR signaling in glioma cells with the allosteric mTORC1 inhibitor rapamycin, the mTORC1/2 inhibitor Ku-0063794, a dual PI3K/mTORC1/2 kinase inhibitor PI-103, and siRNA against raptor, rictor, or mTOR, and evaluated the value of mTOR inhibitors for the treatment of glioblastoma.

PMID:
22125077
[PubMed - indexed for MEDLINE]
PMCID:
PMC3402221
Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk